What Is the Optimal Treatment Modality in Molecularly Defined Secondary AML? a Multicenter Cohort Study
Shai Shimony(Twitter (United States)), Maximilian Stahl(Harvard University), Jorge Ramos(Seagen (United States)), Evan C. Chen(Dana-Farber Cancer Institute), Aaron D. Goldberg(Memorial Sloan Kettering Cancer Center), Brian Ball(City Of Hope National Medical Center), Eva J. Schaefer(Dana-Farber Cancer Institute), Guido Marcucci(City of Hope), Eytan M. Stein(Memorial Sloan Kettering Cancer Center), Amer M. Zeidan(Yale Cancer Center), Richard M. Stone(Dana-Farber Cancer Institute), R. Coleman Lindsley(Harvard University), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Jan Philipp Bewersdorf(Memorial Sloan Kettering Cancer Center), Rory M. Shallis(Smilow Cancer Hospital), Donna Neuberg(Otsuka (Japan)), Yiwen Liu(University of Arizona), Anthony S. Stein(University of Hohenheim)
Cited by 2
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k